Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07832461 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ANCILLARY STUDY No. 3 NS-PARK-OMICS

Study acronym: NS-PARK-OMICS
StatusNot Yet Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Minor Study First Submitted
The goal of this clinical study is to identify biomarkers associated with Parkinson's disease (PD) progression in PD patients, participants at-risk of developing PD (e.g., a person who does not have the disease but carrying a mutation known to be related to the disease or a person with a prodromal form as iRBD for example), as well as healthy volunteers. The working hypothesis of this study is that patients with Parkinson's disease can be stratified into etiological subgroups through the integration of omics data. Combining molecular signatures with longitudinal clinical and phenotypic data from the NS-PARK cohort will enable the development of disease progression models grounded in the pathophysiological mechanisms of Parkinson's disease. Researchers will compare the data with those from healthy volunteers to determine whether the findings are specific to PD, as some biomarkers may reflect broader processes related to neurodegeneration, aging, or comorbidities. In this ancillary study, in addition to the NS-PARK cohort assessments, participants will be proposed to do, during one visit: * A lumbar puncture * A blood draw * A urine collection * An olfactory test * A more detailed neuropsychological assessment
Trial Details
NCT Number NCT07832461
Lead Sponsor Institut National de la Santé Et de la Recherche Médicale, France
Conditions
(from sponsor)
PARKINSON DISEASE (Disorder)
Related terms Parkinson Disease
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov